Results of an open, observational, non-interventional study of the efficacy and safety of etoricoxib (Dolocox) in osteoarthritis of various localizations (knee joint, hip joint) Etoricoxib (Dolocox) Observational Study (EDONIS)”
Bibliographic record
Abstract
Osteoarthritis (OA) is the most common joint disease, the first line of treatment for which are non-steroidal anti-inflammatory drugs. In terms of sufficient duration for pain relief and minimization of the risk of adverse events (AE), it seems relevant to evaluate the efficacy and safety of a short course of OA therapy with the drug etoricoxib (Dolocox®). The aim of the study was to evaluate the clinical efficacy (effect on the activity of the inflammatory process, intensity of pain) and safety of etoricoxib (Dolocox®) in a short course of therapy (at least 10 days) in the treatment of osteoarthritis. Material and methods. 60 patients were included, of which 55% (33) had comorbidities. Pain was assessed using the visual analogue scale (VAS), symptoms of knee OA – using the WOMAC (Western Ontario and McMaster University) scale, and patient satisfaction with their condition – using the PASS (Patient Acceptable Symptom State) index. The dynamics of symptoms, adverse events, and tolerability were recorded daily. Etoricoxib (Dolocox®) was prescribed to patients by the physician at a dose of 60 mg once daily in the morning for 10 days. Differences were statistically significant at p<0.05. Results. With etoricoxib (Dolocox®) on day 10 pain decreased at movement from 55,3 to 19,4 (p<0.05), at rest – from 50,3 to 18,5 (p<0.05), at night – from 46,6 to 17,6 (p<0.05). Reduce of pain of 40% and more was observed during movement in 92%, at rest – in 87%, at night – in 90% of patients on day 10. According to the WOMAC, on day 10, a decrease of more than 40% of all subscales was noted (“Pain” – 45%, “Stiffness” – 53%, “Function” – 45% of patients); positive PASS was recorded in 97% of patients. 75% of participants rated tolerability as excellent, 23% – as good. Physicians noted excellent tolerability in 70% (42) cases, good – in 28% (17). AEs were reported in 7% of patients, all of them are mild. Conclusions. Etoricoxib (Dolocox®) is highly effective in the treatment of knee and hip OA in a short course of therapy, which allows its use in real clinical practice.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.005 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".